# Mitor Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mitor-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.mitorpharm.com/
- Latest round: Seed (Apr 10, 2026)
- Investors on record: 1

## About

Mitor Pharmaceuticals, based in Chengdu, China, is focused on developing innovative therapies primarily in oncology, addressing critical unmet medical needs through advanced drug formulation.Founded in 2024, Mitor Pharmaceuticals specializes in the research and development of oncology therapeutics. The company has engaged in 2 significant deals, with its most recent transaction occurring on April 10, 2026. There are no known subsidiaries or parent companies involved in its operations.Mitor Pharmaceuticals specializes in the development and commercialization of innovative therapeutic products that target unmet medical needs in oncology. Their offerings include proprietary drug formulations aimed at specific cancer-related pathways, which enhance treatment efficacy while minimizing side effects. The products are marketed internationally, including in North America and Europe, serving healthcare providers, hospitals, and specialty clinics dedicated to cancer treatment.Mitor Pharmaceuticals generates revenue through direct sales to healthcare providers and partnerships with pharmaceutical distributors. Their client base largely consists of hospitals and cancer treatment centers that procure products in bulk. Competitive pricing strategies reflect the company’s extensive R&D investments, and tiered pricing plans may apply to bulk purchases, fostering strong client relationships within the healthcare sector.In April 2026, Mitor Pharmaceuticals secured an undisclosed amount of Seed funding from Chengdu Science and Technology Venture Capital Group. The company intends to allocate this funding towards advancing the preclinical development of its ClpP small molecule agonist pipelines, strengthening IND enabling studies, and constructing an integrated R&D platform for early-stage innovative oncology and immunomodulatory drug discovery.

## Funding rounds

- Seed, Apr 10, 2026 — Chengdu Science and Technology Venture Capital Group

## Investors

- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Seed